Bolt Biotherapeutics, Inc. BOLT
6.30 USD -0.12 (-1.87%)
At closeNov 10, 2026, 6:15 PM EST
6.26 -0.04 -0.60%
After hours · Nov 10, 6:15 PM ET
6.20 Day range 6.66
3.10 52-week range 7.78
- YTD
- +15.17%
- 1 year
- +28.05%
News
globenewswire.com INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU? NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and…
prnewswire.com INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU? /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for
globenewswire.com Bolt Biotherapeutics to Participate in Upcoming Conferences REDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”), a clinical-stage biotechnology company pioneering a new generation of…
seekingalpha.com Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript
prnewswire.com $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) NEW YORK, Oct. 26, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…
benzinga.com Bolt’s Acquisition Positions It To Advance Prana’s Inspire Multispecific Antibody Pipeline; Phase 2 PRA-216 Readouts Expected Starting Q2 2027 Prana’s Pipeline Overview and Development MilestonesPrana’s focus is to develop the next generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. The…
benzinga.com Bolt Biotherapeutics Secures $120M Private Placement, With Potential Additional $60M From Warrant Exercise To Fund Operations Into 2028 Concurrent with the acquisition, Bolt entered into a definitive agreement for a private placement financing to raise $120 million in gross proceeds, for the purchase of 13,995.311 shares of Series D…
benzinga.com Bolt Biotherapeutics Acquires Prana Therapies In Sign-And-Close Reverse Merger, Shifts Focus To Multispecific Antibody Pipeline; Prana Holders to Own 51.7% of Combined Company, Backed by Up To $180M Financing Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform PRA-216 is a novel…
globenewswire.com Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”) today announced the acquisition of Prana Therapies, Inc. (“Prana”), a…
defenseworld.net Bolt Biotherapeutics (NASDAQ:BOLT) Share Price Breaks Above Two Hundred Day Moving Average – Time to Sell? Shares of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of…
defenseworld.net Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below 200-Day Moving Average – Should You Sell? Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.23 and traded as…
defenseworld.net Bolt Biotherapeutics (NASDAQ:BOLT) VP Sarah Nemec Sells 4,077 Shares Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) VP Sarah Nemec sold 4,077 shares of Bolt Biotherapeutics stock in a transaction on Friday, September 18th. The shares were sold at an…
defenseworld.net Bolt Biotherapeutics (NASDAQ:BOLT) COO Grant Yonehiro Sells 4,909 Shares of Stock Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) COO Grant Yonehiro sold 4,909 shares of the firm's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million. Sionna Therapeutics (NASDAQ:SION)…
zacks.com Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks Consensus Estimate of a loss of $2.97. This compares to a loss of $4.46 per share a year ago.
benzinga.com Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses…
globenewswire.com Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of…
accessnewswire.com Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), is pleased to announce that, further to its press releases dated May…
benzinga.com Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22 Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $22.- benzinga.com HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
zacks.com Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $5.8 per share a year ago.
benzinga.com Bolt Biotherapeutics Q1 EPS $(4.31) Misses $(2.85) Estimate, Sales $26.000K Miss $1.500M Estimate Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.31) per share which missed the analyst consensus estimate of $(2.85) by 51.23 percent. This is a 25.69 percent increase over losses…
globenewswire.com Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,…
defenseworld.net Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Grows By 355.3% Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling…- benzinga.com HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
zacks.com Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks Consensus Estimate of a loss of $4.3. This compares to a loss of $7.6 per share a year ago.- benzinga.com Bolt Biotherapeutics Q4 EPS $(3.84) Beats $(4.30) Estimate, Sales $2.500M Beat $666.667K Estimate Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(3.84) per share which beat the analyst consensus estimate of $(4.30) by 10.7 percent. This is a 49.47 percent increase over losses of…
globenewswire.com Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,…
defenseworld.net Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two…
globenewswire.com Bolt Biotherapeutics to Participate in Upcoming March Conferences REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Bolt Biotherapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS (FOR THE TREATMENT OF CANCER)". https://x.com/PatentGrants/status/1998150771544928598?s=20
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
benzinga.com Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket - benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 112 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's session, 406 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 210 companies reached new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 152 stocks made new 52-week lows.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.